

## Editorial on management of diabetes mellitus with coronary artery disease

Wilbert S. Aronow

Cardiology Division, New York Medical College, Valhalla, USA

\*Published in cooperation with the American Society for Preventive Cardiology (ASPC)

**Submitted:** 4 December 2011

**Accepted:** 5 December 2011

Arch Med Sci 2011; 7, 6: 928-930

DOI: 10.5114/AOMS.2011.26601

Copyright © 2011 Termedia & Banach

**Corresponding author:**

Wilbert S. Aronow, MD  
Cardiology Division  
New York Medical College  
Macy Pavilion, Room 138  
Valhalla, NY 10595  
Phone: (914) 493-5311  
Fax: (914) 235-6274  
E-mail: wsaronow@aol.com

The review article by Athyros *et al.* [1] is an excellent review article. I concur with the issues discussed by the authors. This editorial discusses my current approach to the management of patients with diabetes mellitus and coronary artery disease (CAD).

Patients with diabetes mellitus and CAD should be treated with optimal medical management. All modifiable risk factors should be treated. Patients should be strongly encouraged to stop smoking and be referred to a smoking cessation program.

Hypertension should be treated with the blood pressure reduced to < 140/90 mmHg [2]. The initial drug of choice should be an angiotensin-converting enzyme (ACE) inhibitor [2].

The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial enrolled 4,162 patients with an acute coronary syndrome (acute myocardial infarction with or without ST-segment elevation or high-risk unstable angina pectoris) [3]. The lowest cardiovascular events rates occurred with a systolic blood pressure between 130 mmHg to 140 mmHg and a diastolic blood pressure between 80 mmHg to 90 mmHg with a nadir of 136/85 mmHg. An observational subgroup analysis was performed in 6,400 of the 22, 576 persons enrolled in the International Verapamil SR-Trandolapril Study (INVEST) who had diabetes and CAD [4]. Persons were categorized as having tight control of blood pressure if they could maintain their systolic blood pressure below 130 mmHg and their diastolic blood pressure below 85 mmHg, usual control if they could maintain their systolic blood pressure between 130 mmHg to 139 mmHg, and uncontrolled if their systolic blood pressure was 140 mmHg or higher.

During 16,893 patient-years of follow-up, a cardiovascular event rate of 12.6% occurred in patients with usual control of blood pressure vs. 19.8% in patients with uncontrolled hypertension,  $p < 0.001$ . The incidence of cardiovascular events was 12.6% in patients with usual control of blood pressure vs. 12.7% in patients with tight control of blood pressure. The all-cause mortality rate was 11.0% with tight control of blood pressure vs. 10.2% with usual control of blood pressure ( $p = 0.06$ ). When extended follow-up was included, the all-cause mortality rate was 22.8% with tight control of blood pressure vs. 21.8% with usual control of blood pressure,  $p = 0.04$ .

Dyslipidemia should be treated. The serum low-density lipoprotein cholesterol should be reduced to < 70 mg/dl [5-7].

Diabetes mellitus should be treated with the hemoglobin A<sub>1c</sub> reduced to < 7.0%. Hypoglycemia must be avoided in patients with CAD. In 10, 251

high-risk diabetics in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study, patients randomized to intensive treatment reached a hemoglobin A<sub>1c</sub> of 6.4%, and patients randomized to conventional treatment reached a hemoglobin level of 7.5% [8]. At 3.5-year follow-up, intensive therapy increased mortality 22% from 4.0% to 5.0% ( $p = 0.04$ ) and did not significantly reduce major cardiovascular events.

Obese diabetics with CAD must lose weight by dietary therapy and by aerobic physical activity. They should exercise for at least 30 min daily for 7 days per week with a minimum of 5 days of physical exercise per week [9].

Diabetics with CAD should be treated with aspirin, ACE inhibitors,  $\beta$ -blockers, and statins to reduce cardiovascular events and mortality and coronary revascularization [6, 9-13]. Angina pectoris should be treated with  $\beta$ -blockers and nitrates [14]. If angina persists, I would add a calcium channel blocker, and if needed, ranolazine.

In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, of 2,248 patients with stable CAD randomized to optimal medical therapy plus percutaneous coronary intervention (PCI) vs. optimal medical therapy alone, 766 patients (34%) had diabetes mellitus, and 1,362 patients (61%) had the metabolic syndrome [15].

At 4.6-year median follow-up, the risk of death or myocardial infarction in patients with diabetes mellitus and in patients with the metabolic syndrome was similar in patients with and without early PCI. On the basis of these data, I would not recommend early PCI to patients with diabetes mellitus or the metabolic syndrome who have stable CAD.

In the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, 2,368 patients with diabetes mellitus and CAD were randomized to undergo either prompt coronary revascularization with intensive medical therapy or intensive medical therapy alone and to undergo either insulin-sensitization or insulin-provision therapy [16]. Randomization was stratified according to the choice of PCI or coronary artery bypass grafting (CABG). At 5-year follow-up, survival was 88.3% for the coronary revascularization group and 87.8% for the medical therapy alone group ( $p$  not significant) and 88.2% for the insulin-sensitization group and 87.9% for the insulin-provision group ( $p$  not significant). The incidence of freedom from major cardiovascular events was also not significantly different between the coronary revascularization and medical therapy alone groups and between the insulin-sensitization and insulin provision groups. In the PCI stratum, the primary endpoints of death and of death or major cardiovascular events were

similar in the PCI and medical therapy alone groups. However, in the CABG stratum, the incidence of death or myocardial infarction or stroke was 22.4% in the CABG group vs. 30.5% in the medical therapy alone group ( $p = 0.01$ ) [16].

In the BARI 2D trial, 1,191 patients were randomized to optimal medical therapy alone and 1,173 patients to coronary revascularization with 796 patients preselected for PCI and 377 patients to CABG [17]. Compared with the medical therapy group alone, at 3-year follow-up, the coronary revascularization group had a lower incidence of worsening angina pectoris (8% vs. 13%,  $p < 0.001$ ), a lower incidence of new angina pectoris (37% vs. 51%,  $p = 0.001$ ), a lower incidence of subsequent coronary revascularization (18% vs. 33%,  $p < 0.001$ ), and a higher incidence of angina-free status (66% vs. 58%,  $p = 0.003$ ). The CABG patients were at higher risk than the PCI patients and had the greatest benefits from coronary revascularization. The symptomatic benefits were observed particularly for high-risk patients.

These data favor optimal medical therapy alone in patients with diabetes mellitus and stable CAD. However, if disabling angina pectoris despite optimal medical therapy occurs, I would recommend coronary revascularization. In high-risk patients, I would recommend CABG over PCI at this time. At 10.4-year follow-up of diabetics with CAD in the BARI trial, the CABG group had a survival rate of 57.8% vs. 45.5% for the PCI group ( $p = 0.025$ ) and a subsequent coronary revascularization incidence of 20.3% for the CABG group vs. 76.8% for the PCI group ( $p < 0.001$ ) [18].

On the basis of the available data, I would treat patients with diabetes mellitus and ST-segment elevation myocardial infarction [19] or unstable angina/non-ST-segment elevation myocardial infarction [20] with coronary revascularization with the choice of PCI or CABG depending on the coronary angiographic findings. The blood sugar in these patients should have a target goal between 140-180 mg/dl. Diabetics who have received stents should be treated with dual antiplatelet therapy for at least 1 year after PCI and preferably longer.

## Acknowledgments

The author has no conflicts of interest. He has no affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

## References

1. Athyros VG, Gossios TD, Tziomalos K, et al. Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable

- angina who are already on optimal medical treatment? *Arch Med Sci* 2011; 7: 1067-75.
2. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European society of Hypertension. *J Am Coll Cardiol* 2011; 57: 2037-114.
  3. Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. *Circulation* 2010; 122: 2142-51.
  4. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. *JAMA* 2010; 304: 61-8.
  5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004; 110: 227-39.
  6. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and of new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol  $\geq 125$  mg/dl treated with statins. *J Gerontol Med Sci* 2002; 57A: M747-50.
  7. Ravipati G, Aronow WS, Kumber S, et al. Patients with diabetes mellitus with ischemic stroke have a higher hemoglobin A<sub>1c</sub> level and a higher serum low-density lipoprotein cholesterol level than diabetics without ischemic stroke. *Arch Med Sci* 2009; 5: 391-3.
  8. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 2008; 358: 2545-59.
  9. Smith SC Jr, Allen J, Blair SN, et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *Circulation* 2006; 113: 2363-72.
  10. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. *Am J Cardiol* 2001; 87: 780-1.
  11. Aronow WS, Ahn C, Kronzon I. Reductions of incidences of new coronary events and of congestive heart failure by beta blockers alone, by angiotensin-converting enzyme inhibitors alone, and by beta blockers plus angiotensin-converting enzyme inhibitors in older persons with prior myocardial infarction and asymptomatic left ventricular systolic dysfunction. *Am J Cardiol* 2001; 88: 1298-300.
  12. Lai HM, Aronow WS, Mercado AD, et al. The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. *Med Sci Monit* 2011; 17: CR683-6.
  13. Mercado AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events through use of aggressive risk factor reduction medications: a retrospective study in an outpatient cardiology practice. *Arch Med Sci* 2012; 8 (in press).
  14. Aronow WS, Frishman WH. Angina in the elderly. In: Aronow WS, Fleg JL, Rich MW (eds): *Cardiovascular disease in the elderly*. Fourth edition, New York city, Informa Healthcare, 2008, pp 269-92.
  15. Maron DJ, Boden WE, Spertus JA, et al. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug evaluation) trial. *J Am Coll Cardiol* 2011; 58: 131-7.
  16. The BARI 2 D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009; 360: 2503-15.
  17. Dagenais GR, Lu J, Faxon DP, et al. Effect of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. *Circulation* 2011; 123: 1492-500.
  18. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 2007; 49: 1600-6.
  19. Kushner FG, Hand M, Smith SC, Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA /SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2009; 120: 2271-306.
  20. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2011; 57: 1920-59.